FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Clears Ezra Flash AI for MRI Quality

[ Price : $8.95]

FDA clears an Ezra 510(k) for its artificial intelligence-enabled Ezra Flash and its use in enhancing MR image quality.

CDER Drug Policy Guru Heads to Morgan Lewis

[ Price : $8.95]

CDER Office of New Drug Policy director Maarika Kimbrell leaves the agency to re-enter private legal practice at Morgan Lewis as a...

Clinical Hold on PepGen IND Application

[ Price : $8.95]

FDA places a clinical hold on a PepGen IND application for a Phase 1 trial of PGN-EDODM1 to treat myotonic dystrophy Type 1.

Precision BioSciences to Meet with FDA on Azer-Cel

[ Price : $8.95]

Precision BioScience says it will meet with FDA in June to discuss a regulatory way forward through a Phase 2 trial for its azer-c...

Groups Want Regulation of Lab-Developed Tests

[ Price : $8.95]

Sixteen advocacy organizations urge FDA to regulate laboratory-developed tests if Congress fails to produce a strong bill.

Junshi Bio Inspection to Advance Toripalimab BLA

[ Price : $8.95]

FDA completes a previously delayed pre-licensing inspection of China-based Shanghai Junshi Biosciences breakthrough cancer drug to...

FDA/EU MRA Now Includes Animal Inspections

[ Price : $8.95]

FDA and the European Union agree to expand the scope of the U.S.-EU mutual recognition agreement to include inspections of veterin...

FDA to Permit In-Person End-of-Phase 2 Meetings

[ Price : $8.95]

FDA says that beginning 6/12 it will expand in-person industry meetings to include requests for Type B End-of-Phase 2 requests at ...

CDRH Committee to Discuss Health Equity

[ Price : $8.95]

CDRH announces a 9/6 Patient Engagement Advisory Committee meeting to discuss and make recommendations on Advancing Health Equity ...

Sanofi Multiple Sclerosis Trial Meets Endpoint

[ Price : $8.95]

Sanofi says data from a Phase 2 trial of frexalimab significantly reduced disease activity in patients with relapsing multiple scl...